BACARDI-LIMITED
Thousands of bars and restaurants could soon be serving cocktails for the first time as TAILS kicks off a campaign to demonstrate how pre-batched cocktails are a hassle-free solution for driving revenue just when the hospitality industry needs it most.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005560/en/
The premium batched cocktail brand, acquired by family-owned Bacardi in November, is delivering 10,000 sample kits to newly reopened on-trade outlets across Europe as part of an initiative to highlight how anyone, in any type of bar or restaurant, can serve quality cocktails easily, quickly, consistently and at scale – and at the same time generate a welcome new revenue stream.
Evert-Jan Bos, General Manager, TAILS, said: “During lockdown, people have been buying their own cocktail shakers and watching ‘how to’ videos so they can create cocktails at home. As the on-trade now reopens, interest in cocktails has exploded and demand far exceeds the number of outlets serving them. That gap in the market, makes this the perfect time for local bars to offer cocktails for the first time and create their first ever cocktail menus.
“There are no obstacles,” says Evert-Jan. “TAILS opens up the world of premium cocktails to bars which may think they need specialist training, lots of ingredients and don’t have the time to make cocktails. In fact, the 15 seconds it takes to create a premium cocktail with TAILS, more than pays back in increased profit.”
A QR code on the back of every 1L bottle of TAILS links to a ‘how to’ video. The same QR code is on a menu inside each sample kit along with 20cl bottles of the entire TAILS range of classic and contemporary cocktails all crafted using the Bacardi portfolio of premium brands. They include the Classic and Berry Mojito, both made with BACARDĺ® rum; the Passion Fruit and Espresso martini cocktails, both made with 42BELOW® vodka; and the Garden Spritz made with BOMBAY® gin and ST-GERMAIN® elderflower liqueur.
Since it was established in London 10 years ago, TAILS has perfected the crafting and batching of exceptional tasting cocktails in bottles or on draft making them more accessible to people whether they are in a small, local bar or a major music festival.
Following its acquisition by Bacardi, TAILS has now expanded to every market in Western Europe, with more international markets to follow.
In and out of lockdown, Bacardi has been helping its on-trade partners maximize their revenue and is continuing to help them get back on their feet through its ongoing #RaiseYourSpirits initiative.
Always drink responsibly
About TAILS
TAILS crafts expertly batched cocktails to ensure consistent quality and speed of service throughout the hospitality and events industry. Established in 2010, the TAILS mission is to make premium cocktails more accessible and deliver perfectly served cocktails at scale. Using only the finest ingredients including natural flavors, juices and infusions, TAILS offers a broad range of both contemporary and classic cocktails in both multi-serve 1L bottles and on draft. They include the Classic and Berry Mojito, both made with BACARDĺ® rum; the Passion Fruit and Espresso martini cocktails, both made with 42BELOW® vodka; and the Garden Spritz made with BOMBAY® gin and ST-GERMAIN® elderflower liqueur. TAILS cocktails are available in selected bars across 11 markets in Western Europe. The TAILS brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited.
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, 42BELOW® vodka and ERISTOFF® vodka. Founded more than 159 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005560/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
